Use of Biologic Therapies With Different Mechanisms of Action (MOA) in the First-line (1L) Treatment of Crohn's Disease (CD) in the US

被引：0
作者：
Huang, Zhongwen [1 ]
Ba, Yi [1 ]
Kamble, Pravin [1 ]
Wang, Song [1 ]
机构：
[1] Takeda, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S917
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [21] Dose Escalation of Biologic Therapies in Biologic Treatment-Naive Patients With Crohn's Disease: Results From the ODESSA-CD Study
    Cleveland, Noa Krugliak
    Kathe, Niranjan
    Umashankar, Kandavadivu
    Mirchandani, Kirti
    Hait, Arunima
    Paul, Riyanka
    Ghosh, Sabyasachi
    Candela, Ninfa
    Fan, Tao
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10) : S570 - S571
  • [22] REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC VEDOLIZUMAB IN CROHN'S DISEASE: ANALYSIS OF HIGHER TREATMENT EFFECT SUBPOPULATION FROM THE EVOLVE STUDY
    Yarur, Andres
    Bressler, Brian
    Wang, Song
    Adsul, Shashi
    Kamble, Pravin
    Luo, Michelle
    Cook, Erin
    Sajeev, Gautam
    Dieye, Ibou
    Mantzaris, Gerassimos J.
    GASTROENTEROLOGY, 2021, 160 (06) : S4 - S4
  • [23] 4 Years of Experience with Vedolizumab (Entyvio®) as a First-line Biologic for Treating Ulcerative Colitis and Crohn's Disease in Clinic and Practice
    不详
    VISCERAL MEDICINE, 2018, 34 (05) : 400 - 400
  • [24] First-Line Treatment Options for Ileocecal Crohn's Disease: Early Surgical Resection or Biologics? Reply
    Agrawal, Manasi
    Colombel, Jean-Frederic
    Allin, Kristine H.
    GASTROENTEROLOGY, 2024, 166 (02) : 363 - 364
  • [25] Patterns of care in renal cell carcinoma (RCC): Impact of duration of first-line (1L) treatment on second-line (2L) treatment choice
    Feinberg, Bruce A.
    Garofalo, David
    Drenning, Jason
    Montgomery, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Sotelo, Miguel
    Chara, Luis
    Riquelme, Alejandro
    Toro, Piedad
    Lopez, Cynthia
    Hernando, Susana
    Caviedes, Edinson
    Aguayo, Cristina
    Bueno, Coralia
    Mielgo Rubio, Xabier
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
  • [27] Vedolizumab: First-line Biologic for Ulcerative colitis and Crohn's Disease Real-world Data shows continued stable Disease Progression
    Ruedesheim, Sabine M.
    VISCERAL MEDICINE, 2023, 39 (3-4) : 100 - 100
  • [28] Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)
    Mato, Anthony R.
    Ravelo, Arliene
    MyTo, Tu
    Schuldt, Robert
    Biondo, Juliana M. L.
    BLOOD, 2021, 138
  • [29] Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
    Geynisman, Daniel M.
    Kish, Jonathan K.
    Falkenstein, Angelica
    Huo, Stephen
    Del Tejo, Viviana
    Rosenblatt, Lisa
    Guttenplan, Sarah
    Balanean, Alexandrina
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US).
    Tran, Nguyen H.
    Soefje, Scott A.
    Rangarajan, Nivedita
    Purushotham, K.
    Nadig, Mihika
    Wagner, Tyler E.
    Valerio, Stephen J.
    Anderson, Rye
    Olson, Jody C.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 572 - 572
12345